May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal sophisticated technologies that drive creation of new drug discovery programs in key therapeutic areas Kallyope 2022 – Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope

Modulators in Neurological Disorders at Jefferies Healthcare Conference in London Sosei Heptares and Kallyope